COMBOGESIC IV
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COMBOGESIC IV (COMBOGESIC IV).
Combination of acetaminophen (paracetamol) and ibuprofen. Acetaminophen: Weak COX inhibition in CNS, analgesic and antipyretic. Ibuprofen: Non-selective COX-1/COX-2 inhibition, anti-inflammatory, analgesic, antipyretic.
| Metabolism | Acetaminophen: Hepatic via conjugation (glucuronidation, sulfation) and CYP2E1 (minor) to reactive metabolite NAPQI. Ibuprofen: Hepatic via CYP2C9 and CYP2C8 to inactive metabolites. |
| Excretion | Renal: 90% as glucuronide conjugates and unchanged drug for paracetamol; biliary: 10% for paracetamol. For tramadol: renal 90% (unchanged and metabolites), fecal 10%. |
| Half-life | Paracetamol: 1.5-3 hours; tramadol: 6 hours (active metabolite M1: 7-9 hours). Clinical context: Extended half-life in hepatic impairment (cirrhosis) and elderly; requires dose adjustment. |
| Protein binding | Paracetamol: 10-25% bound to albumin; tramadol: 20% bound to albumin; active metabolite M1: negligible binding. |
| Volume of Distribution | Paracetamol: 0.9 L/kg; tramadol: 2.7 L/kg (wide distribution into tissues). Clinical meaning: High Vd for tramadol indicates extensive tissue distribution. |
| Bioavailability | IV: 100% for both components. Oral: Paracetamol 85-90%; tramadol 75% (first-pass metabolism). Not applicable for IM/SC routes. |
| Onset of Action | IV: Paracetamol onset within 5 minutes; tramadol onset within 5-10 minutes. Peak effect at 1 hour for both. |
| Duration of Action | Paracetamol: 4-6 hours (analgesia); tramadol: 4-6 hours (analgesia). Clinical notes: Duration may be prolonged with high doses or in renal impairment. |
1 vial (1000 mg paracetamol + 60 mg codeine phosphate) IV infusion over 15 minutes, every 4-6 hours as needed, max 4 vials per day.
| Dosage form | SOLUTION |
| Renal impairment | eGFR 30-50 mL/min: administer every 6 hours; eGFR <30 mL/min: not recommended; dialysis: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated. |
| Pediatric use | Children >12 years and ≥50 kg: same as adult dose; <12 years or <50 kg: not recommended due to codeine; use alternative analgesic. |
| Geriatric use | Initiate at lowest effective dose; monitor for respiratory depression and hypotension; consider reduced dose or extended interval due to age-related clearance decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COMBOGESIC IV (COMBOGESIC IV).
| Breastfeeding | Acetaminophen: Low transfer into breast milk, M/P ratio 0.91-1.42; considered compatible with breastfeeding. Ibuprofen (if applicable, assuming NSAID component): M/P ratio 0.01-0.06, very low levels; considered compatible. Avoid NSAIDs if infant has thrombocytopenia or renal impairment. Monitor infant for rash, drowsiness, or gastrointestinal effects. |
| Teratogenic Risk | First trimester: Avoid combination acetaminophen/NSAIDs due to potential cardiovascular and neural tube defects with NSAIDs; acetaminophen considered relatively safe but limit use. Second trimester: NSAIDs associated with oligohydramnios and fetal renal effects; acetaminophen safe at therapeutic doses. Third trimester: NSAIDs contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal renal impairment; acetaminophen preferred. |
■ FDA Black Box Warning
Risk of severe hepatic injury with acetaminophen; do not exceed maximum daily dose (4 g/day).
| Serious Effects |
Hypersensitivity to any component, active GI bleeding, severe hepatic impairment, severe renal impairment (CrCl <30 mL/min), history of asthma/urticaria with NSAIDs, perioperative pain in CABG surgery.
| Precautions | Hepatotoxicity (acetaminophen overdose), GI bleeding/ulceration (ibuprofen), renal impairment, cardiovascular thrombotic events (ibuprofen), anaphylactic reactions, masking of infection signs. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, renal function (creatinine, BUN), and signs of gastrointestinal bleeding; fetal monitoring for amniotic fluid index (oligohydramnios) and ductus arteriosus Doppler if used beyond 20 weeks gestation. Assess fetal growth if prolonged use. |
| Fertility Effects | NSAIDs may impair female fertility by inhibiting prostaglandin synthesis, affecting ovulation and implantation; reversible upon discontinuation. Acetaminophen not associated with fertility impairment. No documented effect on male fertility. |